Spyre Therapeutics closed at $99.04 on Nov 4, down 0.23%, 9.1% below its 52-week closing high. Volume of 1.5M shares was 1.29× its 20-day average (above normal).
Split-adjusted performance: +23.6% over one month, +35.7% over six months, +316.5% over one year.
Short interest was 12.5M shares at the Oct 15 settlement, down 2.6% from the prior report (15.6% of float, 7.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SYRESpyre Therapeutics | $99.04 | −0.23% | +35.7% | — | — | — | $9.26B | |
| MDGLMadrigal Pharmaceuticals | $400.43 | +1.04% | −25.8% | +50.1% | 12.9% | — | $9.25B | Compare |
| PTGXProtagonist Therapeutics | $143.37 | +2.23% | +37.9% | +3749.2% | 76.3% | 111.9 | $9.28B | Compare |
| TGTXTG Therapeutics | $61.63 | +1.45% | +46.8% | +70.3% | 3.2% | 21.4 | $9.43B | Compare |
| CYTKCytokinetics | $63.60 | +2.07% | −15.0% | −57.1% | −694.4% | — | $8.84B | Compare |
| ARWRArrowhead Research | $61.65 | +3.56% | −22.1% | +171.0% | −258.2% | — | $8.71B | Compare |
| CORTCorcept Therapeutics | $79.22 | −3.31% | +51.9% | +31.7% | 16.8% | 157.2 | $8.56B | Compare |
| PRAXPraxis Precision Medicines | $284.79 | +1.53% | −15.8% | — | — | — | $7.95B | Compare |
| BMRNBioMarin Pharmaceuticals | $57.13 | +2.64% | +4.6% | +19.9% | 4.5% | 151.5 | $11.06B | Compare |
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
